Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q3 2018 · 10-Q
Revenue$944.00K$944.00K−42.1% vs Q3 2017 Net Income-$9.01M-$9.01MN/M vs Q3 2017 EPS Diluted-$0.29-$0.29N/M vs Q3 2017 Operating Income-$9,151,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,007,000N/M Margins · derivedOperating margin-969.4%−608.3 pt vs Q3 2017
Net margin-954.6%−596.9 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 7, 2018 · 38 d after period end